Stella Pharma Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	-176	-137	-760	-775	-764	-656
Depreciation & Amortization	31	34	35	35	34	31
Other Operating Activities	-5	-2	-1	-2	-	-4
Change in Accounts Receivable	-505	-638	-16	-42	38	-55
Change in Inventory	-151	-114	-175	-166	-380	-87
Change in Accounts Payable	42	-88	26	108	-13	38
Change in Other Net Operating Assets	39	1,085	15	15	4	-39
Operating Cash Flow	-725	140	-876	-827	-1,081	-772
Capital Expenditures	-10	-4	-10	-26	-46	-21
Sale (Purchase) of Intangibles	-	-8	-	-3	-	-1
Investment in Securities	200	300	-	-	-304	-
Other Investing Activities	-	-1	1	-	-	-
Investing Cash Flow	190	287	-9	-29	-350	-22
Long-Term Debt Issued	-	730	-	-	-	-
Long-Term Debt Repaid	-	-946	-160	-160	-160	-160
Net Debt Issued (Repaid)	-215	-216	-160	-160	-160	-160
Issuance of Common Stock	-	941	388	451	3,616	199
Other Financing Activities	-3	-4	-	-	373	-371
Financing Cash Flow	-223	721	228	291	3,829	-332
Miscellaneous Cash Flow Adjustments	-1	1	-	-	-1	-2
Net Cash Flow	-759	1,149	-657	-565	2,397	-1,128
Free Cash Flow	-735	136	-886	-853	-1,127	-793
Free Cash Flow Margin	-74.09%	14.15%	-329.37%	-372.49%	-1127.00%	-386.83%
Free Cash Flow Per Share	-21.60	4.07	-28.60	-29.54	-40.13	-39.58
Cash Interest Paid	5	4	2	2	3	3
Cash Income Tax Paid	2	2	2	3	-	4
Levered Free Cash Flow	-703.13	-859.75	-612.25	-569	-828	-571.5
Unlevered Free Cash Flow	-700	-857.25	-611	-567.75	-826.13	-569.63
Change in Working Capital	-575	245	-150	-85	-351	-143

Source: S&P Global Market Intelligence. Standard template. Financial Sources.